AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03241485
Drug: Intrathecal morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 micrograms/kilogram of intrathecal morphine administered in the spinal space, not to exceed 1mg
Trial: NCT00208715
Drug: Provigil
RxNorm normalized name: Provigil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002362
Drug: Abacavir sulfate
RxNorm normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01617824
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Linagliptin 5 mg tablets for 4 days
Trial: NCT00002362
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002362
Drug: Emtricitabine
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002362
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00295555
Drug: Effects of doxazosin on morning surge in diabetic patients
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001658
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02761330
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine will be used to induce general anesthesia with or without subsequent ECT. Within a single patient, the dose will remain consistent throughout the study and is estimated to be 2 mg/kg.
Trial: NCT00999102
Drug: Metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol 50 mg, Metoprolol 100 mg,
Trial: NCT00999102
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg, Nebivolol 10 mg.
Trial: NCT00746382
Drug: Roflumilast cream
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast cream 0.5% versus Placebo cream
Trial: NCT00602602
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00602602
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00210496
Drug: topiramate; almotriptan malate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04246684
Drug: Oxaliplatin, 85 mg/m2
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m2,2h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapy
Trial: NCT01668017
Drug: Pimasertib
RxNorm normalized name: Pimasertib
DrugBank: Pimasertib (DB14904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with solid tumor will be administered with Pimasertib 30 mg twice a day (BID) in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Trial: NCT01668017
Drug: Pimasertib
RxNorm normalized name: Pimasertib
DrugBank: Pimasertib (DB14904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with solid tumor will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Trial: NCT01668017
Drug: Pimasertib
RxNorm normalized name: Pimasertib
DrugBank: Pimasertib (DB14904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with solid tumor will be administered with Pimasertib 60 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Trial: NCT01668017
Drug: Pimasertib
RxNorm normalized name: Pimasertib
DrugBank: Pimasertib (DB14904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with HCC will be administered with Pimasertib 30 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Trial: NCT01668017
Drug: Pimasertib
RxNorm normalized name: Pimasertib
DrugBank: Pimasertib (DB14904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with HCC will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Trial: NCT00553319
Drug: Adderall-XR
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adderall-XR 60mg/day
Trial: NCT00553319
Drug: Adderall-XR
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adderall-XR 80mg/day
Trial: NCT04246684
Drug: Oxaliplatin 50 mg/m2
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/m2, 2h-civ, d1, d8, d21, d29 of radiotherapy and
Trial: NCT04246684
Drug: Oxaliplatin 85 mg/m2
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m2, 2h-civ, d64, d78, d92, d106, d120, d134 of therapy
Trial: NCT04246684
Drug: Oxaliplatin, 130 mg/m2
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: day1every three weeks (optional)
Trial: NCT03216525
Drug: Alvimopan
RxNorm normalized name: Alvimopan
DrugBank: Alvimopan (DB06274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To determine if Alvimopan during radical cystectomy with urinary diversion results in faster return of bowel function.
Trial: NCT00888134
Drug: Selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03083613
Drug: Raltitrexed
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed:3mg/m2,iv,d1, Every 3 weeks
Trial: NCT03083613
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel:80mg/m2,iv,d1,d8, Every 3 weeks
Trial: NCT00508118
Drug: Nicardipine
RxNorm normalized name: Nicardipine
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: on bypass
Trial: NCT00427687
Drug: AGG-523
RxNorm normalized name: AGG-523
DrugBank: AGG-523 (DB15460)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00896402
Drug: Skin antisepsis with chlorhexidine
RxNorm normalized name: Skin antisepsis, oral cleansing, nasal antisepsis KIT
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine swabs will be used to antiseptically clean the skin, then cultures of the skin and femoral nerve block catheters will be analyzed via standard microbiological techniques
Trial: NCT00896402
Drug: povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine swabs will be used to antiseptically clean the skin; then cultures of the skin and femoral nerve catheters will be performed by standard microbiologic techniques
Trial: NCT03901755
Drug: Alprolix
RxNorm normalized name: Alprolix
DrugBank: Eftrenonacog alfa (DB11608)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Extended half-life factor IX product
Trial: NCT00720291
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who are randomly assigned to receive Metronidazole will receive 500 mg po bid Metronidazole for 7 days
Trial: NCT01229592
Drug: Heparine
RxNorm normalized name: Heparine
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every three day lock using Heparin(Fibrilin TM) 3ml in all the lumen of the Catheter
Trial: NCT00021346
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00021346
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00367146
Drug: MMF
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03774446
Drug: Seliciclib
RxNorm normalized name: Seliciclib
DrugBank: Seliciclib (DB06195)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Seliciclib
Trial: NCT05737927
Drug: Glucose 16 g coated beads (47% w/w)
RxNorm normalized name: GLUCOSE 1,6-BISPHOSPHATE
DrugBank: Alpha-D-Glucose 1,6-Bisphosphate (DB02835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After an overnight fasting of about 10 hours, the subjects were administered 16 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
Trial: NCT05737927
Drug: Glucose 12 g coated beads (60% w/w)
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After an overnight fasting of about 10 hours, the subjects were administered the coated Glucose beads formulation (60 % w/w glucose/bead; 12 g glucose) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
Trial: NCT01212627
Drug: Ridaforolimus
RxNorm normalized name: Ridaforolimus
DrugBank: Ridaforolimus (DB06233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus 20 Daily, 5 days each week, (Mon-Fri) on a 28 day cycle
Trial: NCT00759551
Drug: Azilsartan
RxNorm normalized name: Azilsartan
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan 2.5 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
Trial: NCT00759551
Drug: Azilsartan
RxNorm normalized name: Azilsartan
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan 5.0 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
Trial: NCT00759551
Drug: Azilsartan
RxNorm normalized name: Azilsartan
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan 10 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
Trial: NCT00759551
Drug: Azilsartan
RxNorm normalized name: Azilsartan
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan 20 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
Trial: NCT00759551
Drug: Azilsartan
RxNorm normalized name: Azilsartan
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan 40 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
Trial: NCT00759551
Drug: Olmesartan
RxNorm normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan placebo-matching tablets, orally, once daily and olmesartan 20 mg, capsules, orally, once daily for up to 8 weeks.
Trial: NCT00372905
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
Trial: NCT00372905
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
Trial: NCT00372905
Drug: Ibritumomab tiuxetan
RxNorm normalized name: ibritumomab tiuxetan
DrugBank: Ibritumomab tiuxetan (DB00078)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
Trial: NCT03587961
Drug: Symdeko
RxNorm normalized name: Symdeko
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
Trial: NCT01728454
Drug: Telapristone acetate
RxNorm normalized name: Telapristone acetate
DrugBank: Telapristone acetate (DB05253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telapristone acetate capsules, orally once daily for 18 weeks.
Trial: NCT04487275
Drug: MLC901 or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: groups randomly assigned to receive either MLC901 or placebo capsules three times per day over 6 months
Trial: NCT04366869
Drug: Botox
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botox injection i masseter in temporalis
Trial: NCT02613910
Drug: Ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab (human monoclonal antibody) will be provided as a liquid concentrate in a prefilled glass syringe with staked needle, stopper, and plunger containing 0.4 millilitre (mL) (20 mg) drug product of 50 mg/mL concentration
Trial: NCT02613910
Drug: Antihistamine (cetirizine or equivalent)
RxNorm normalized name: Ahist Antihistamine
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antihistamine (cetirizine or equivalent) will be supplied by study center as 10 mg tablet, caplet, capsule or liquid for oral administration
Trial: NCT02613910
Drug: Prednisone/Prednisolone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone/Prednisolone will be supplied from the dose range 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200, 220 and 240 mg for oral administration
Trial: NCT03187314
Drug: SHR-1210
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
Trial: NCT03266159
Drug: GSK525762 Besylate tablets
RxNorm normalized name: Ergoloid Mesylates Tablets
DrugBank: Ergoloid mesylate (DB01049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK525762 Besylate film coated tablets will be available as a 20 mg tablet strength, yellowish pink in color, round and biconvex with no markings. It will be administered with 240mL of liquid.
Trial: NCT03266159
Drug: Trametinib tablets
RxNorm normalized name: Trametinib Tablets
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib film coated tablets will be available as 0.5 mg and 2 mg dose strengths. Trametinib 0.5 mg will be yellow colored, modified oval, biconvex, tablets with 'GS' debossed on one face and 'TFC' on the opposing face.~Trametinib 2 mg will be pink colored, round, biconvex tablets with 'GS' debossed on one face and 'HMJ' on the opposing face. Doses will be taken at least 1 hour before or at least 2 hours after a meal.
Trial: NCT04033328
Drug: ORIC-101
RxNorm normalized name: Oriconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ORIC-101 once daily in each 28-day cycle
Trial: NCT04033328
Drug: enzalutamide 40 MG oral capsule [Xtandi]
RxNorm normalized name: ENZALUTAMIDE 40 mg ORAL CAPSULE [Xtandi]
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 160 mg once daily in each 28-day cycle
Trial: NCT03747497
Drug: linezolid 600 mg
RxNorm normalized name: linezolid 600 MG
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV and oral linezolid given twice a day for 10 to 14 days
Trial: NCT01106066
Drug: Oxaliplatin, S-1, radiotherapy
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Radiotherapy 4000cGy/20 fractions S-1 ( )mg/m2 po bid daily during radiotherapy Oxaliplatin at four dose levels (___mg/m2 iv weekly x 4 weeks)
Trial: NCT02094066
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
Trial: NCT02094066
Drug: serum physiologic
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preoperative 100 cc ıv serum physiologic
Trial: NCT02058966
Drug: Entacapone
RxNorm normalized name: Entacapone
DrugBank: Entacapone (DB00494)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entacapone 200 mg oral dose
Trial: NCT02058966
Drug: Methamphetamine
RxNorm normalized name: Methamphetamine
DrugBank: Metamfetamine (DB01577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methamphetamine 20 mg oral dose
Trial: NCT04156087
Drug: Durvalumab 50 MG/ML
RxNorm normalized name: durvalumab 50 MG/ML
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest.
Trial: NCT04156087
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest.
Trial: NCT04156087
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest.
Trial: NCT00323479
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg/Day oral
Trial: NCT00136994
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00451776
Drug: etomidate
RxNorm normalized name: Etomidate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients who received etomidate
Trial: NCT00451776
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients who received propofol
Trial: NCT02679560
Drug: Liposomal Bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A fascia iliaca compartment block using liposomal bupivacaine will require less total opioid administration compared to a fascia iliaca block using 0.2% ropivacaine
Trial: NCT02679560
Drug: Ropivacaine HCL
RxNorm normalized name: ropivacaine HCl
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine HCL is a member of the amino amide class of local anesthetics. Naropin injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. It is administered parenterally.
Trial: NCT00638248
Drug: Desmoteplase
RxNorm normalized name: Desmoteplase
DrugBank: Desmoteplase (DB04925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmoteplase 90µg/kg BW i.v. bolus
Trial: NCT00638248
Drug: Desmoteplase
RxNorm normalized name: Desmoteplase
DrugBank: Desmoteplase (DB04925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmoteplase 125 µg/kg BW i.v. bolus